Cutmore Lauren C, Marshall John F
Barts Cancer Institute, Cancer Research UK Centre of Excellence, Queen Mary University of London, London EC1M 6BQ, UK.
Cancers (Basel). 2021 Apr 16;13(8):1926. doi: 10.3390/cancers13081926.
CAR T cells have revolutionised the treatment of haematological malignancies. Despite this, several obstacles still prohibit their widespread use and efficacy. One of these barriers is the use of autologous T cells as the carrier of the CAR. The individual production of CAR T cells results in large variation in the product, greater wait times for treatment and higher costs. To overcome this several novel approaches have emerged that utilise allogeneic cells, so called "off the shelf" CAR T cells. In this Review, we describe the different approaches that have been used to produce allogeneic CAR T to date, as well as their current pre-clinical and clinical progress.
嵌合抗原受体（CAR）T细胞彻底改变了血液系统恶性肿瘤的治疗方式。尽管如此，仍有几个障碍阻碍了它们的广泛应用和疗效。其中一个障碍是使用自体T细胞作为CAR的载体。CAR T细胞的个体化生产导致产品差异很大，治疗等待时间更长，成本更高。为了克服这一问题，出现了几种利用同种异体细胞的新方法，即所谓的“现成可用”CAR T细胞。在本综述中，我们描述了迄今为止用于生产同种异体CAR T细胞的不同方法，以及它们目前的临床前和临床进展。
